Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02301884 | Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis | PHASE1 | COMPLETED | 12 | — | — | Nov 1, 2013 | Mar 1, 2015 | Mar 11, 2015 | 1 | South Korea |
Rhinoconjunctivitis Quality of Life Questionnaire
| Arm | Type | Description |
|---|---|---|
| Allergen extract | EXPERIMENTAL | Causal allergen such as D. farinae (30 AU/ml), D. pteronyssinus (30 AU/ml), cat hair (10 AU/ml), dog hair/dander (1:1/10 w/v), or combination of those. Allergen extract, HollisterStier, New Orleans, USA. Intralymphatic injection in volume of 0.1 ml, three times with 4-week interval. Concentration was increased, decreased, or unchanged at 2nd or 3rd injection according to local or systemic reaction after previous injection |
| Name | Type | Description |
|---|---|---|
| Allergen extract | BIOLOGICAL | Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those |
Inclusion Criteria: * Allergic rhinitis to house dust mite (Df, Dp), cat or dog * More than 3mm reaction at skin prick test for Df, Dp, cat or dog or more than class 3 at serum specific IgE level (UNICAP or MAST) Exclusion Criteria: * Uncontrolled or severe asthma according to Global Initiative o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | NA | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | — | Undisclosed |